Literature DB >> 15312138

Monocytosis and accelerated activation of lymphocytes in C1q-deficient autoimmune-prone mice.

Marten Trendelenburg1, Anthony P Manderson, Liliane Fossati-Jimack, Mark J Walport, Marina Botto.   

Abstract

C1q deficiency has been shown to accelerate spontaneous autoimmunity in mice. We studied the time course of activation of monocytes and lymphocytes in autoimmune and non-autoimmune mice in the presence or absence of C1q as a disease accelerator. Autoimmune MRL\Mp.C1qa-\- and non-autoimmune C57BL\6.C1qa-\- mice were analysed at various time points between 6 and 33 weeks of age and compared to strain- and age-matched C1q-sufficient controls. Splenic and peritoneal leucocytes were analysed by flow cytometry and plasma levels of immunoglobulin M (IgM), total IgG, IgG subclasses and IgM autoantibodies were measured. Both C1q-deficient strains had significantly more splenic monocytes than their controls at all time points analysed. In addition, MRL\Mp.C1qa-\- but not C57BL/6.C1qa-\- mice developed splenic hypercellularity starting at about 12-17 weeks old, had signs of accelerated CD4+ T-cell activation and showed a marked increase in splenic plasma cells and total serum IgM levels from about 22 weeks of age. The accelerated CD4+ T-cell activation was not due to a direct inhibitory effect of C1q on T cells. These data show that C1q deficiency causes splenic monocytosis together with accelerated T-cell activation in an autoimmune-prone mouse strain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312138      PMCID: PMC1782548          DOI: 10.1111/j.1365-2567.2004.01940.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies.

Authors:  M Botto; C Dell'Agnola; A E Bygrave; E M Thompson; H T Cook; F Petry; M Loos; P P Pandolfi; M J Walport
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

2.  Lupus-prone mice have an abnormal response to thioglycolate and an impaired clearance of apoptotic cells.

Authors:  Paul K Potter; Josefina Cortes-Hernandez; Pierre Quartier; Marina Botto; Mark J Walport
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

3.  C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited.

Authors:  L C Korb; J M Ahearn
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

Review 4.  Opsonization of apoptotic cells and its effect on macrophage and T cell immune responses.

Authors:  Sun Jung Kim; Debra Gershov; Xiaojing Ma; Nathan Brot; Keith B Elkon
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

5.  A critical role for complement in maintenance of self-tolerance.

Authors:  A P Prodeus; S Goerg; L M Shen; O O Pozdnyakova; L Chu; E M Alicot; C C Goodnow; M C Carroll
Journal:  Immunity       Date:  1998-11       Impact factor: 31.745

6.  Human T cells express specific binding sites for C1q. Role in T cell activation and proliferation.

Authors:  A Chen; S Gaddipati; Y Hong; D J Volkman; E I Peerschke; B Ghebrehiwet
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

Review 7.  C1q and systemic lupus erythematosus.

Authors:  M J Walport; K A Davies; M Botto
Journal:  Immunobiology       Date:  1998-08       Impact factor: 3.144

8.  Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus.

Authors:  M Herrmann; R E Voll; O M Zoller; M Hagenhofer; B B Ponner; J R Kalden
Journal:  Arthritis Rheum       Date:  1998-07

9.  Systemic exposure to irradiated apoptotic cells induces autoantibody production.

Authors:  D Mevorach; J L Zhou; X Song; K B Elkon
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

10.  Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes.

Authors:  L A Casciola-Rosen; G Anhalt; A Rosen
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  7 in total

1.  Novel collectin/C1q receptor mediates mast cell activation and innate immunity.

Authors:  Brian T Edelson; Thomas P Stricker; Zhengzhi Li; S Kent Dickeson; Virginia L Shepherd; Samuel A Santoro; Mary M Zutter
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

2.  Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury.

Authors:  Manuel D Galvan; Sabina Luchetti; Adrian M Burgos; Hal X Nguyen; Mitra J Hooshmand; Frank P T Hamers; Aileen J Anderson
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

3.  Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis.

Authors:  L A Trouw; N Daha; F A S Kurreeman; S Böhringer; G N Goulielmos; H J Westra; A Zhernakova; L Franke; E A Stahl; E W N Levarht; G Stoeken-Rijsbergen; W Verduijn; A Roos; Y Li; J J Houwing-Duistermaat; T W J Huizinga; R E M Toes
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

4.  Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms.

Authors:  Peng Gao; Yan Jiao; Qing Xiong; Cong-Yi Wang; Ivan Gerling; Weikuan Gu
Journal:  Curr Genomics       Date:  2008       Impact factor: 2.236

Review 5.  Emerging and Novel Functions of Complement Protein C1q.

Authors:  Lubna Kouser; Shanmuga Priyaa Madhukaran; Abhishek Shastri; Anuvinder Saraon; Janez Ferluga; Maha Al-Mozaini; Uday Kishore
Journal:  Front Immunol       Date:  2015-06-29       Impact factor: 7.561

6.  Anti-C1q autoantibodies from systemic lupus erythematosus patients enhance CD40-CD154-mediated inflammation in peripheral blood mononuclear cells in vitro.

Authors:  Pascal Alexander Rabatscher; Marten Trendelenburg
Journal:  Clin Transl Immunology       Date:  2022-08-02

7.  C1q as a target molecule to treat human disease: What do mouse studies teach us?

Authors:  Kristina Schulz; Marten Trendelenburg
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.